Drug Trial Radar · NCT04213261
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Actual
Start
Jun 9, 2020
Primary completion
Jan 17, 2023
Study completion Jul 2037
Sponsor
- Lead sponsor
- Castle Creek Biosciences, LLC.Industry
- Sponsor type
- Industry
- First posted
- Dec 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether administration of FCX-007 in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa. Funding Source - FDA OOPD
Conditions
- Recessive Dystrophic Epidermolysis Bullosa
Interventions
FCX-007 (dabocemagene autoficel; see below for FCX-007 description)Biological
FCX-007 is comprised of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete Wound Closure of the First Wound Pair at Week 24Time frame: Week 24
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Stanford University
Stanford, California
Children's Hospital Colorado
Aurora, Colorado
Solutions Through Advanced Research, Inc.
Jacksonville, Florida
Mayo Clinic
Rochester, Minnesota
Dell Children's Medical Group
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.